Actively Recruiting
Open-label Phase IbII Study of GFH276 Combined With Cetuximab or Chemotherapy for Advanced Solid Tumors and Pancreatic Ductal Adenocarcinoma With RAS Mutation
Led by Genfleet Therapeutics (Shanghai) Inc. · Updated on 2026-10-05
222
Participants Needed
17
Research Sites
43 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, tolerability, and preliminary anti-tumor effects of oral GFH276 combined with cetuximab or standard chemotherapy in adults with locally advanced or metastatic RAS-mutated solid tumors and pancreatic ductal adenocarcinoma PDAC. This open-label, multicenter Phase IbII trial aims to find the best dose for further study and evaluate treatment outcomes in this patient group. Participants will be assigned to one of three treatment groups GFH276 with cetuximab given intravenously every two weeks, GFH276 with nab-paclitaxel plus gemcitabine on cycles of three or four weeks, or GFH276 with mFOLFIRINOX chemotherapy given every two weeks. The Phase Ib stage involves increasing GFH276 doses to identify dose-limiting toxicities and safety, followed by Phase II expansion to assess anti-tumor effectiveness and long-term safety of each combination. During the study, participants will undergo tumor imaging, laboratory tests, adverse event monitoring, and blood sampling to study drug levels. Treatment continues until disease worsens, unacceptable side effects occur, consent is withdrawn, or the study ends. Safety and response will be followed for up to 24 months, with detailed assessments of adverse events, tumor response, and pharmacokinetics included.
CONDITIONS
Brief Title
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
Research Team
B
Bai Li
Z
Zhang Pingping
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here